冠心病介入手术后阿托伐他汀对冠脉再狭窄的影响

目的：观察经皮冠状动脉介入（PCI）术后患者服用阿托伐他汀后血清低密度脂蛋白-胆固醇（LDL—C）水平达标情况及其与冠脉再狭窄的关系。方法：选择我院因冠心病行PCI术患者91例，术后除接受抗血小板等常规治疗外，均服用阿托伐他汀（20mg／d），6～18月后再次行冠脉造影术（CAG），根据CAG评分结果患者被分为病变进展组（n=32）和病变未进展组（n=59）；又根据第二次手术前LDL—C水平分为LDL-C≥2．1mmol／L（n=43），1．64LDL—c〈2．1mmol／L（n=30），LDL—C〈1．6mmol／L（n=18）三亚组，并探讨其相关性。结果：与病变未进展组患者比较，病变进展组LDL-C降低幅度（0．46±0．81）mmol／L比（-0．04±0．65）mmol／L]，降低百分比（13．18±31．67）％比（-8．21±37．22）％]明显减小（P均〈0．05）；LDL-C≥2．1mmol／L组，1．6≤LDL-C〈2．1mmol／L组，LDL-C〈1．6mmol／L组病变未进展者比例逐渐升高（58．1％比63．3％比83．3％，P〈0．05）；Spearman分析显示，CAG前LDL水平与冠脉评分呈负相关（r=-0．70，P〈0．0001）。结论：常规治疗量的阿托伐他汀可使多数患者低密度脂蛋白胆固醇水平达标并有效遏制冠心病患者冠脉再狭窄。

Influence of atorvastatin on coronary artery restenosis in patients with coronary heart disease after percutaneous coronary intervention

Objective:To observe influence of atorvastatin on coronary artery restenosis in patients with coronary heart disease(CHD) after percutaneous coronary intervention(PCI).Methods:A total of 91 CHD patients undergoing PCI were selected from our hospital.Besides routine treatment such as antiplatelet therapy after PCI,all patients received atorvastatin(20mg/ d) and they underwent coronary angiography(CAG) again after 6～18 months.According to CAG results,patients were divided into disease progression group(n=32) and disease no-progression group(n=59);according to LDL-C level before followed CAG,patients were divided into LDL-C≥2.1mmol/ L group(n=43),1.6≤LDL-C<2.1mmol/ L group(n=30) and LDL-C<1.6mmol/ L group(n=18),and their correlation with CAG score was analyzed.Results:Compared with disease no-progression group,there were significant decrease in decrease extent of LDL-C (0.46±0.81)mmol/ L vs.(-0.04±0.65)mmol/ L] and decrease percentage of LDL-C (13.18±31.67)% vs.(-8.21±37.22)%] in disease progression group,P<0.05 both;ratio of patients with disease no-progression progressively increased in LDL-C≥2.1mmol/ L group,1.6≤LDL-C<2.1mmol/ L group and LDL-C<1.6mmol/ L group(58.1% vs.63.3% vs.83.3%,P<0.05) in order;Spearman analysis indicated that LDL-C level before CAG was negatively correlated with CAG score(r=-0.70,P<0.0001).Conclusion:Atorvastatin could make low density lipoprotein cholesterol level up to the standard for treatment in most patients and it can effectively prevent coronary artery restenosis.